Previous Article | Next Article ![]()
Clinical and Diagnostic Laboratory Immunology, July 2000, p. 540-548, Vol. 7, No. 4
University of California, Los
Angeles,1 University of California, San
Diego,3 and University of
California, San Francisco,6
Statistical and Data Analysis Center, Harvard School of Public
Health, Boston, Massachusetts2;
Rush-Presbyterian-St. Luke's Medical Center, Chicago,
Illinois4; University of North Carolina,
Chapel Hill, North Carolina5;
University of Washington, Seattle,
Washington7; Children's Hospital of
Philadelphia, Philadelphia Pennsylvania8;
MD Anderson Cancer Center and Baylor College of Medicine,
Houston,9 and University of Texas
Medical Branch, Galveston,10 Texas;
University of Colorado Health Sciences Center, Denver,
Colorado11; University of Miami
School of Medicine, Miami, Florida12;
Albert Einstein Medical Center New York, New
York13; and FAST Systems, Gaithersburg,
Maryland14
Received 2 November 1999/Returned for modification 3 February
2000/Accepted 18 March 2000
An external evaluation program for measuring the performance of
laboratories testing for cytokines and immune activation markers in
biological fluids was developed. Cytokines, chemokines, soluble cytokine receptors, and other soluble markers of immune activation (CSM) were measured in plasma from a healthy human immunodeficiency virus (HIV)-seronegative reference population and from HIV-seropositive individuals as well as in supernatant fluids from in vitro-stimulated human immune cells. The 14 components measured were tumor necrosis factor (TNF) alpha, gamma interferon, interleukin-1 (IL-1), IL-2, IL-4,
IL-6, IL-10, Rantes, MIP-Ia, MIP-I
1071-412X/00/$04.00+0
Copyright © 2000, American Society for Microbiology. All rights reserved.
Need for an External Proficiency Testing Program
for Cytokines, Chemokines, and Plasma Markers of Immune
Activation








, soluble TNF receptor II, soluble
IL-2 receptor alpha,
2-microglobulin, and neopterin. Twelve laboratories associated with the Adult and Pediatric AIDS Clinical Trial Groups participated in the study. The performance features that were evaluated included intralaboratory variability, interlaboratory variability, comparison of reagent sources, and ability
to detect CSM in the plasma of normal subjects as well as the changes
occurring in disease. The principal findings were as follows: (i) on
initial testing, i.e., before participating in the program,
laboratories frequently differed markedly in their analytic results;
(ii) the quality of testing of a CSM in individual participating
laboratories could be assessed; (iii) most commercial kits allowed
distinction between normal and abnormal plasma CSM levels and between
supernatants of stimulated and unstimulated cells; (iv) different
sources of reagents and reference standards frequently provided
different absolute values; (v) inexperienced laboratories can benefit
from participating in the program; (vi) laboratory performance improved
during active participation in the program; and (vii) comparability
between analyses conducted at different sites can be ensured by an
external proficiency testing program.
*
Corresponding author. Mailing address: Department of
Microbiology and Immunology, UCLA School of Medicine, Los Angeles, CA 90095-1747. Phone: (310) 825-6568. Fax: (310) 206-1318. E-mail: jlfahey{at}microimmun.medsch.ucla.edu.
Affiliated with Pediatric ACTG Immunology Laboratories.
Copyright © 2009 by the American Society for Microbiology. For an alternate route to Journals.ASM.org, visit: http://intl-journals.asm.org | More Info»